Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Racepinephrine is a racemic mixture of d-epinephrine and l-epinephrine enantiomers. It is a small molecule bronchodilator used for the temporary relief of mild symptoms of intermittent asthma such as wheezing, chest tightness, and shortness of breath. Racepinephrine acts as a non-selective agonist at alpha-adrenergic receptor and beta-adrenergic receptor (including α1, α2A, β1, and β2), leading to relaxation of airway smooth muscle (bronchodilation) and improved airflow. It is available over-the-counter in inhalation form for use with nebulizers or atomizers[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on racepinephrine.